Sumitomo Pharma , Ltd. Receivables

The latest receivables for DNPUF is $140B as of June 2026. That compares with $83B in the prior-year period — up 67.3% year over year. Investors often review this figure alongside Sumitomo Pharma , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, DNPUF's receivables moved from $83B to $140B — a 67.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sumitomo Pharma , Ltd.'s operating scale or balance-sheet position.

A receivables figure of $140B for DNPUF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting DNPUF's receivables ($140B), review year-over-year change from $83B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.